<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00230607</url>
  </required_header>
  <id_info>
    <org_study_id>AGAL02603</org_study_id>
    <secondary_id>2006-001910-33</secondary_id>
    <secondary_id>MSC12868</secondary_id>
    <nct_id>NCT00230607</nct_id>
  </id_info>
  <brief_title>Study of the Effects of Fabrazyme Treatment on Lactation and Infants</brief_title>
  <official_title>A Multicenter, Multinational Study of the Effects of Fabrazyme (Agalsidase Beta) Treatment on Lactation and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will last for up to 2 years (24 months). Full participation for both mother and
      infant is 24 months, full participation of mother and development of infant is 24 months,
      while full participation of mother and no infant participation is 6 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NOTE: Estimated Enrollment: 10 mothers and up to 10 infants
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2006</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of pharmacokinetic parameters of αGAL in breast milk: Cmax</measure>
    <time_frame>Month 1, 3, and 6</time_frame>
    <description>Maximum concentration (Cmax) of αGAL in breast milk</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of pharmacokinetic parameters of αGAL in breast milk: AUC0-2h</measure>
    <time_frame>Month 1, 3, and 6</time_frame>
    <description>Area under the plasma αGAL concentration-time curve (AUC) from 0 to 2 hours post end of infusion (AUC0-2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of pharmacokinetic parameters of αGAL in breast milk: lactation clearance</measure>
    <time_frame>Month 1, 3, and 6</time_frame>
    <description>Lactation clearance will be estimated as the amount of αGAL excreted over the sampling period divided by the AUC during the sampling period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of breast milk</measure>
    <time_frame>Baseline, Month 2, 6, and 12</time_frame>
    <description>Determination of volume of breast milk sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fat content of breast milk</measure>
    <time_frame>Baseline, Months 2, 6, and 12</time_frame>
    <description>Determination of total fat content in breast milk sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protein content of breast milk</measure>
    <time_frame>Baseline, Months 2, 6, and 12</time_frame>
    <description>Determination of total protein content in breast milk sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Growth response of infants</measure>
    <time_frame>Months 1, 2, 3, 6, 12, 18 and Month 24</time_frame>
    <description>Absolute change in growth of infants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development response of infants</measure>
    <time_frame>Months 1, 2, 3, 6, 12, 18 and Month 24</time_frame>
    <description>Absolute change in weight of infants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunologic response of infants - IgG</measure>
    <time_frame>Baseline, Months 2, 6, and 12</time_frame>
    <description>Formation or presence of immunoglobulin G (IgG) antibodies to recombinant human α galactosidase A (r-hαGAL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunologic response of infants - IgM</measure>
    <time_frame>Baseline, Months 2, 6, and 12</time_frame>
    <description>Formation or presence of immunoglobulin M (IgM) antibodies to recombinant human α galactosidase A (r-hαGAL)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Fabry Disease</condition>
  <condition>Alpha Galactosidase A Deficiency</condition>
  <arm_group>
    <arm_group_label>Agalsidase beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Commercially available Fabrazyme treatment at prescribed dose and regimen as determined by their treating physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>agalsidase beta</intervention_name>
    <description>Pharmaceutical form: powder for reconstitution Route of administration: intravenous</description>
    <arm_group_label>Agalsidase beta</arm_group_label>
    <other_name>r-hαGAL</other_name>
    <other_name>Fabrazyme</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Mothers must meet the following criteria to be enrolled in this study:

          -  provide signed written informed consent to participate in this study,

          -  be enrolled in the Fabry Registry and receiving Fabrazyme while lactating,

          -  agree to adhere to the Fabry Registry recommended schedule of assessments for medical
             history, pregnancy outcome, genotyping, and antibody testing, and

          -  agree to adhere to the schedule of evaluations for this study.

        Infants must meet the following criteria to be enrolled in this study:

          -  have the signed written informed consent of the parent(s)/legal guardian(s) to
             participate in this study,

          -  be born to a mother who is receiving Fabrazyme during lactation,

          -  be receiving breast milk from the mother, and

          -  have the agreement of the parent(s)/legal guardian(s) to adhere to the schedule of
             evaluations for this study.

        Exclusion Criteria:

          -  The mother and infant will be excluded from this study if the mother has received an
             investigational drug within 30 days prior to study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>1 then #</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 29, 2005</study_first_submitted>
  <study_first_submitted_qc>September 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2005</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alpha Galactosidase A</keyword>
  <keyword>aGAL</keyword>
  <keyword>rh aGAL</keyword>
  <keyword>Fabry</keyword>
  <keyword>GL3</keyword>
  <keyword>Fabrazyme</keyword>
  <keyword>Lysosomal Storage Disorder</keyword>
  <keyword>Enzyme Replacement Therapy (ERT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

